NEW YORK (GenomeWeb) – As part of its effort to focus on its molecular diagnostics business, PDI announced today that it has agreed to sell off its biomedical commercialization and marketing services business to Publicis Group for up to roughly $48 million.

PDI also said it will assume the name of its molecular diagnostics subsidiary, Interpace Diagnostics, and chance its Nasdaq trading symbol to IDXG. The sale is expected to close in the fourth quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.